Blau syndrome is an early-onset granulomatous disease known to affect the skin, joints, and eyes. We report a child with diffuse rash, arthritis, and subconjunctival nodules. Biopsy of the bulbar conjunctiva revealed noncaseating lipogranulomas that lead to a diagnosis of Blau syndrome. To our knowledge, noncaseating lipogranulomas of the conjunctiva have not been reported previously as a presenting finding in Blau syndrome. Although uveitis is the classic manifestation, it is important to broaden the awareness of other ocular signs, as these variations can aid in diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaapos.2017.05.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Basic, clinical, and translational studies of Yao syndrome and other NOD2 related diseases.
Front Immunol
November 2024
Division of Rheumatology, Allergy and Immunology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, United States.
Blau syndrome mimics Takayasu's arteritis: Report of 2 cases with literature review.
Rheumatol Immunol Res
September 2024
Department of Rheumatology and Immunology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan Province, China.
Comprehensive clinical phenotype, genotype and therapy in Yao syndrome.
Front Immunol
October 2024
Division of Rheumatology, Allergy and Immunology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, United States.
Article Synopsis
- Yao syndrome (YAOS) is an autoinflammatory disease linked to specific genetic variants, with this study analyzing a large group of adult patients diagnosed with related conditions.
- Out of 194 patients studied, 152 were diagnosed with YAOS, while the remainder had mixed autoinflammatory diseases, often showing multiple genetic variants.
- The findings highlight the diverse presentations of YAOS and aim to increase awareness and understanding of this often underrecognized disease among healthcare professionals.
Towards New Anti-Inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP-BIR2.
ChemMedChem
January 2025
Department, Normandie Univ, UNICAEN, CERMN, bd Becquerel, F-14000, Caen, Cedex, France.
Article Synopsis
- XIAP is a protein that helps regulate cell survival and inflammation, and targeting it could benefit diseases like Crohn's disease and sarcoidosis.
- Researchers developed selective inhibitors for a specific part of XIAP (XIAP-BIR2) to disrupt its interaction with RIPK2, which is relevant to inflammatory diseases.
- They created a library of small synthetic molecules, identifying compound 20c, which effectively blocks the NOD1/2 signaling pathway in cells and holds potential as an anti-inflammatory treatment.
: A HERV Turn-On for Autoimmunity, Neurodegeneration, and Cancer?
Microorganisms
September 2024
Department of Biomedical Science, University of Sassari, 07100 Sassari, Italy.
Human endogenous retroviruses (HERVs) are remnants of ancient retroviral infections that, over millions of years, became integrated into the human genome. While normally inactive, environmental stimuli such as infections have contributed to the transcriptional reactivation of HERV-promoting pathological conditions, including the development of autoimmunity, neurodegenerative disease and cancer. What infections trigger HERV activation? subspecies (MAP) is a pluripotent driver of human disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!